H1N1/H3N2 Influenza Variants With Reduced Susceptibility to Baloxavir

The PA-I38 mutations were noted frequently in influenza A/H3N2 viruses compared with A/H1N1pdm or influenza B viruses. The cap-dependent endonuclease inhibitor baloxavir marboxil was approved by the United States Food and Drug Administration in 2018 for the treatment of acute uncomplicated influenza in patients aged >12 years. 1 During […]

Click here to view original web page at www.infectiousdiseaseadvisor.com